GSK3B and breast carcinoma: EGFR-activated AKT inhibits GSK3β activity via Ser9 phosphorylation, suppresses EGF signaling in basal-like breast cancer (BLBC) cells, reduces PD-L1 stability, and decreases cancer cell immune escape, thereby demonstrating a therapeutic benefit.